Copyright Reports & Markets. All rights reserved.

Global Drug, Anti-infective Market Insights and Forecast to 2026

Request for Sample of this report
Buy now

1 Study Coverage

  • 1.1 Drug, Anti-infective Product Introduction
  • 1.2 Market Segments
  • 1.3 Key Drug, Anti-infective Manufacturers Covered: Ranking by Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Drug, Anti-infective Market Size Growth Rate by Type
    • 1.4.2 OTC
    • 1.4.3 Rx Drugs
  • 1.5 Market by Application
    • 1.5.1 Global Drug, Anti-infective Market Size Growth Rate by Application
    • 1.5.2 Hospital
    • 1.5.3 Drugs Store
    • 1.5.4 Other
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Executive Summary

  • 2.1 Global Drug, Anti-infective Market Size, Estimates and Forecasts
    • 2.1.1 Global Drug, Anti-infective Revenue 2015-2026
    • 2.1.2 Global Drug, Anti-infective Sales 2015-2026
  • 2.2 Global Drug, Anti-infective, Market Size by Producing Regions: 2015 VS 2020 VS 2026
    • 2.2.1 Global Drug, Anti-infective Retrospective Market Scenario in Sales by Region: 2015-2020
    • 2.2.2 Global Drug, Anti-infective Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Drug, Anti-infective Competitor Landscape by Players

  • 3.1 Drug, Anti-infective Sales by Manufacturers
    • 3.1.1 Drug, Anti-infective Sales by Manufacturers (2015-2020)
    • 3.1.2 Drug, Anti-infective Sales Market Share by Manufacturers (2015-2020)
  • 3.2 Drug, Anti-infective Revenue by Manufacturers
    • 3.2.1 Drug, Anti-infective Revenue by Manufacturers (2015-2020)
    • 3.2.2 Drug, Anti-infective Revenue Share by Manufacturers (2015-2020)
    • 3.2.3 Global Drug, Anti-infective Market Concentration Ratio (CR5 and HHI) (2015-2020)
    • 3.2.4 Global Top 10 and Top 5 Companies by Drug, Anti-infective Revenue in 2019
    • 3.2.5 Global Drug, Anti-infective Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Drug, Anti-infective Price by Manufacturers
  • 3.4 Drug, Anti-infective Manufacturing Base Distribution, Product Types
    • 3.4.1 Drug, Anti-infective Manufacturers Manufacturing Base Distribution, Headquarters
    • 3.4.2 Manufacturers Drug, Anti-infective Product Type
    • 3.4.3 Date of International Manufacturers Enter into Drug, Anti-infective Market
  • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

  • 4.1 Global Drug, Anti-infective Market Size by Type (2015-2020)
    • 4.1.1 Global Drug, Anti-infective Sales by Type (2015-2020)
    • 4.1.2 Global Drug, Anti-infective Revenue by Type (2015-2020)
    • 4.1.3 Drug, Anti-infective Average Selling Price (ASP) by Type (2015-2026)
  • 4.2 Global Drug, Anti-infective Market Size Forecast by Type (2021-2026)
    • 4.2.1 Global Drug, Anti-infective Sales Forecast by Type (2021-2026)
    • 4.2.2 Global Drug, Anti-infective Revenue Forecast by Type (2021-2026)
    • 4.2.3 Drug, Anti-infective Average Selling Price (ASP) Forecast by Type (2021-2026)
  • 4.3 Global Drug, Anti-infective Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)

  • 5.1 Global Drug, Anti-infective Market Size by Application (2015-2020)
    • 5.1.1 Global Drug, Anti-infective Sales by Application (2015-2020)
    • 5.1.2 Global Drug, Anti-infective Revenue by Application (2015-2020)
    • 5.1.3 Drug, Anti-infective Price by Application (2015-2020)
  • 5.2 Drug, Anti-infective Market Size Forecast by Application (2021-2026)
    • 5.2.1 Global Drug, Anti-infective Sales Forecast by Application (2021-2026)
    • 5.2.2 Global Drug, Anti-infective Revenue Forecast by Application (2021-2026)
    • 5.2.3 Global Drug, Anti-infective Price Forecast by Application (2021-2026)

6 North America

  • 6.1 North America Drug, Anti-infective by Country
    • 6.1.1 North America Drug, Anti-infective Sales by Country
    • 6.1.2 North America Drug, Anti-infective Revenue by Country
    • 6.1.3 U.S.
    • 6.1.4 Canada
  • 6.2 North America Drug, Anti-infective Market Facts & Figures by Type
  • 6.3 North America Drug, Anti-infective Market Facts & Figures by Application

7 Europe

  • 7.1 Europe Drug, Anti-infective by Country
    • 7.1.1 Europe Drug, Anti-infective Sales by Country
    • 7.1.2 Europe Drug, Anti-infective Revenue by Country
    • 7.1.3 Germany
    • 7.1.4 France
    • 7.1.5 U.K.
    • 7.1.6 Italy
    • 7.1.7 Russia
  • 7.2 Europe Drug, Anti-infective Market Facts & Figures by Type
  • 7.3 Europe Drug, Anti-infective Market Facts & Figures by Application

8 Asia Pacific

  • 8.1 Asia Pacific Drug, Anti-infective by Region
    • 8.1.1 Asia Pacific Drug, Anti-infective Sales by Region
    • 8.1.2 Asia Pacific Drug, Anti-infective Revenue by Region
    • 8.1.3 China
    • 8.1.4 Japan
    • 8.1.5 South Korea
    • 8.1.6 India
    • 8.1.7 Australia
    • 8.1.8 Taiwan
    • 8.1.9 Indonesia
    • 8.1.10 Thailand
    • 8.1.11 Malaysia
    • 8.1.12 Philippines
    • 8.1.13 Vietnam
  • 8.2 Asia Pacific Drug, Anti-infective Market Facts & Figures by Type
  • 8.3 Asia Pacific Drug, Anti-infective Market Facts & Figures by Application

9 Latin America

  • 9.1 Latin America Drug, Anti-infective by Country
    • 9.1.1 Latin America Drug, Anti-infective Sales by Country
    • 9.1.2 Latin America Drug, Anti-infective Revenue by Country
    • 9.1.3 Mexico
    • 9.1.4 Brazil
    • 9.1.5 Argentina
  • 9.2 Central & South America Drug, Anti-infective Market Facts & Figures by Type
  • 9.3 Central & South America Drug, Anti-infective Market Facts & Figures by Application

10 Middle East and Africa

  • 10.1 Middle East and Africa Drug, Anti-infective by Country
    • 10.1.1 Middle East and Africa Drug, Anti-infective Sales by Country
    • 10.1.2 Middle East and Africa Drug, Anti-infective Revenue by Country
    • 10.1.3 Turkey
    • 10.1.4 Saudi Arabia
    • 10.1.5 U.A.E
  • 10.2 Middle East and Africa Drug, Anti-infective Market Facts & Figures by Type
  • 10.3 Middle East and Africa Drug, Anti-infective Market Facts & Figures by Application

11 Company Profiles

  • 11.1 GlaxoSmithKline
    • 11.1.1 GlaxoSmithKline Corporation Information
    • 11.1.2 GlaxoSmithKline Description and Business Overview
    • 11.1.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 GlaxoSmithKline Drug, Anti-infective Products Offered
    • 11.1.5 GlaxoSmithKline Related Developments
  • 11.2 Merck
    • 11.2.1 Merck Corporation Information
    • 11.2.2 Merck Description and Business Overview
    • 11.2.3 Merck Sales, Revenue and Gross Margin (2015-2020)
    • 11.2.4 Merck Drug, Anti-infective Products Offered
    • 11.2.5 Merck Related Developments
  • 11.3 Pfizer
    • 11.3.1 Pfizer Corporation Information
    • 11.3.2 Pfizer Description and Business Overview
    • 11.3.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
    • 11.3.4 Pfizer Drug, Anti-infective Products Offered
    • 11.3.5 Pfizer Related Developments
  • 11.4 Novartis AG
    • 11.4.1 Novartis AG Corporation Information
    • 11.4.2 Novartis AG Description and Business Overview
    • 11.4.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
    • 11.4.4 Novartis AG Drug, Anti-infective Products Offered
    • 11.4.5 Novartis AG Related Developments
  • 11.5 Gilead Sciences
    • 11.5.1 Gilead Sciences Corporation Information
    • 11.5.2 Gilead Sciences Description and Business Overview
    • 11.5.3 Gilead Sciences Sales, Revenue and Gross Margin (2015-2020)
    • 11.5.4 Gilead Sciences Drug, Anti-infective Products Offered
    • 11.5.5 Gilead Sciences Related Developments
  • 11.6 Abbott
    • 11.6.1 Abbott Corporation Information
    • 11.6.2 Abbott Description and Business Overview
    • 11.6.3 Abbott Sales, Revenue and Gross Margin (2015-2020)
    • 11.6.4 Abbott Drug, Anti-infective Products Offered
    • 11.6.5 Abbott Related Developments
  • 11.7 Wyeth
    • 11.7.1 Wyeth Corporation Information
    • 11.7.2 Wyeth Description and Business Overview
    • 11.7.3 Wyeth Sales, Revenue and Gross Margin (2015-2020)
    • 11.7.4 Wyeth Drug, Anti-infective Products Offered
    • 11.7.5 Wyeth Related Developments
  • 11.8 Sanofi-Aventis
    • 11.8.1 Sanofi-Aventis Corporation Information
    • 11.8.2 Sanofi-Aventis Description and Business Overview
    • 11.8.3 Sanofi-Aventis Sales, Revenue and Gross Margin (2015-2020)
    • 11.8.4 Sanofi-Aventis Drug, Anti-infective Products Offered
    • 11.8.5 Sanofi-Aventis Related Developments
  • 11.9 Bristol-Myers Squibb
    • 11.9.1 Bristol-Myers Squibb Corporation Information
    • 11.9.2 Bristol-Myers Squibb Description and Business Overview
    • 11.9.3 Bristol-Myers Squibb Sales, Revenue and Gross Margin (2015-2020)
    • 11.9.4 Bristol-Myers Squibb Drug, Anti-infective Products Offered
    • 11.9.5 Bristol-Myers Squibb Related Developments
  • 11.10 Johnson
    • 11.10.1 Johnson Corporation Information
    • 11.10.2 Johnson Description and Business Overview
    • 11.10.3 Johnson Sales, Revenue and Gross Margin (2015-2020)
    • 11.10.4 Johnson Drug, Anti-infective Products Offered
    • 11.10.5 Johnson Related Developments
  • 11.1 GlaxoSmithKline
    • 11.1.1 GlaxoSmithKline Corporation Information
    • 11.1.2 GlaxoSmithKline Description and Business Overview
    • 11.1.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 GlaxoSmithKline Drug, Anti-infective Products Offered
    • 11.1.5 GlaxoSmithKline Related Developments
  • 11.12 Nanosphere
    • 11.12.1 Nanosphere Corporation Information
    • 11.12.2 Nanosphere Description and Business Overview
    • 11.12.3 Nanosphere Sales, Revenue and Gross Margin (2015-2020)
    • 11.12.4 Nanosphere Products Offered
    • 11.12.5 Nanosphere Related Developments
  • 11.13 NanoViricides
    • 11.13.1 NanoViricides Corporation Information
    • 11.13.2 NanoViricides Description and Business Overview
    • 11.13.3 NanoViricides Sales, Revenue and Gross Margin (2015-2020)
    • 11.13.4 NanoViricides Products Offered
    • 11.13.5 NanoViricides Related Developments
  • 11.14 Novabay Pharmaceuticals
    • 11.14.1 Novabay Pharmaceuticals Corporation Information
    • 11.14.2 Novabay Pharmaceuticals Description and Business Overview
    • 11.14.3 Novabay Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
    • 11.14.4 Novabay Pharmaceuticals Products Offered
    • 11.14.5 Novabay Pharmaceuticals Related Developments
  • 11.15 Obetech
    • 11.15.1 Obetech Corporation Information
    • 11.15.2 Obetech Description and Business Overview
    • 11.15.3 Obetech Sales, Revenue and Gross Margin (2015-2020)
    • 11.15.4 Obetech Products Offered
    • 11.15.5 Obetech Related Developments
  • 11.16 Optimer Pharmaceuticals
    • 11.16.1 Optimer Pharmaceuticals Corporation Information
    • 11.16.2 Optimer Pharmaceuticals Description and Business Overview
    • 11.16.3 Optimer Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
    • 11.16.4 Optimer Pharmaceuticals Products Offered
    • 11.16.5 Optimer Pharmaceuticals Related Developments
  • 11.17 Basilea Pharmaceutica AG
    • 11.17.1 Basilea Pharmaceutica AG Corporation Information
    • 11.17.2 Basilea Pharmaceutica AG Description and Business Overview
    • 11.17.3 Basilea Pharmaceutica AG Sales, Revenue and Gross Margin (2015-2020)
    • 11.17.4 Basilea Pharmaceutica AG Products Offered
    • 11.17.5 Basilea Pharmaceutica AG Related Developments
  • 11.18 Daiichi Sankyo
    • 11.18.1 Daiichi Sankyo Corporation Information
    • 11.18.2 Daiichi Sankyo Description and Business Overview
    • 11.18.3 Daiichi Sankyo Sales, Revenue and Gross Margin (2015-2020)
    • 11.18.4 Daiichi Sankyo Products Offered
    • 11.18.5 Daiichi Sankyo Related Developments
  • 11.19 MerLion Pharma
    • 11.19.1 MerLion Pharma Corporation Information
    • 11.19.2 MerLion Pharma Description and Business Overview
    • 11.19.3 MerLion Pharma Sales, Revenue and Gross Margin (2015-2020)
    • 11.19.4 MerLion Pharma Products Offered
    • 11.19.5 MerLion Pharma Related Developments
  • 11.20 Theravance
    • 11.20.1 Theravance Corporation Information
    • 11.20.2 Theravance Description and Business Overview
    • 11.20.3 Theravance Sales, Revenue and Gross Margin (2015-2020)
    • 11.20.4 Theravance Products Offered
    • 11.20.5 Theravance Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)

  • 12.1 Drug, Anti-infective Market Estimates and Projections by Region
    • 12.1.1 Global Drug, Anti-infective Sales Forecast by Regions 2021-2026
    • 12.1.2 Global Drug, Anti-infective Revenue Forecast by Regions 2021-2026
  • 12.2 North America Drug, Anti-infective Market Size Forecast (2021-2026)
    • 12.2.1 North America: Drug, Anti-infective Sales Forecast (2021-2026)
    • 12.2.2 North America: Drug, Anti-infective Revenue Forecast (2021-2026)
    • 12.2.3 North America: Drug, Anti-infective Market Size Forecast by Country (2021-2026)
  • 12.3 Europe Drug, Anti-infective Market Size Forecast (2021-2026)
    • 12.3.1 Europe: Drug, Anti-infective Sales Forecast (2021-2026)
    • 12.3.2 Europe: Drug, Anti-infective Revenue Forecast (2021-2026)
    • 12.3.3 Europe: Drug, Anti-infective Market Size Forecast by Country (2021-2026)
  • 12.4 Asia Pacific Drug, Anti-infective Market Size Forecast (2021-2026)
    • 12.4.1 Asia Pacific: Drug, Anti-infective Sales Forecast (2021-2026)
    • 12.4.2 Asia Pacific: Drug, Anti-infective Revenue Forecast (2021-2026)
    • 12.4.3 Asia Pacific: Drug, Anti-infective Market Size Forecast by Region (2021-2026)
  • 12.5 Latin America Drug, Anti-infective Market Size Forecast (2021-2026)
    • 12.5.1 Latin America: Drug, Anti-infective Sales Forecast (2021-2026)
    • 12.5.2 Latin America: Drug, Anti-infective Revenue Forecast (2021-2026)
    • 12.5.3 Latin America: Drug, Anti-infective Market Size Forecast by Country (2021-2026)
  • 12.6 Middle East and Africa Drug, Anti-infective Market Size Forecast (2021-2026)
    • 12.6.1 Middle East and Africa: Drug, Anti-infective Sales Forecast (2021-2026)
    • 12.6.2 Middle East and Africa: Drug, Anti-infective Revenue Forecast (2021-2026)
    • 12.6.3 Middle East and Africa: Drug, Anti-infective Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

  • 13.1 Market Opportunities and Drivers
  • 13.2 Market Challenges
  • 13.3 Market Risks/Restraints
  • 13.4 Porter's Five Forces Analysis
  • 13.5 Primary Interviews with Key Drug, Anti-infective Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

  • 14.1 Value Chain Analysis
  • 14.2 Drug, Anti-infective Customers
  • 14.3 Sales Channels Analysis
    • 14.3.1 Sales Channels
    • 14.3.2 Distributors

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Research Methodology
      • 16.1.1 Methodology/Research Approach
      • 16.1.2 Data Source
    • 16.2 Author Details

    Drug, Anti-infective market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Drug, Anti-infective market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

    Segment by Type, the Drug, Anti-infective market is segmented into
    OTC
    Rx Drugs

    Segment by Application, the Drug, Anti-infective market is segmented into
    Hospital
    Drugs Store
    Other

    Regional and Country-level Analysis
    The Drug, Anti-infective market is analysed and market size information is provided by regions (countries).
    The key regions covered in the Drug, Anti-infective market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
    The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
    Competitive Landscape and Drug, Anti-infective Market Share Analysis
    Drug, Anti-infective market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Drug, Anti-infective business, the date to enter into the Drug, Anti-infective market, Drug, Anti-infective product introduction, recent developments, etc.

    The major vendors covered:
    GlaxoSmithKline
    Merck
    Pfizer
    Novartis AG
    Gilead Sciences
    Abbott
    Wyeth
    Sanofi-Aventis
    Bristol-Myers Squibb
    Johnson
    Roche Pharma AG
    Nanosphere
    NanoViricides
    Novabay Pharmaceuticals
    Obetech
    Optimer Pharmaceuticals
    Basilea Pharmaceutica AG
    Daiichi Sankyo
    MerLion Pharma
    Theravance

    Buy now